Macrocyclic Orexin-2 Agonists for Narcolepsy Brain Permeability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current compounds with orexin-2 receptor agonist activity are unsatisfactory in terms of activity, pharmacokinetics, permeability into the brain/central nervous system, and safety for treating narcolepsy and related disorders.
Innovation Solution
Development of substituted macrocyclic compounds, represented by Formulas I-A and II-A, which act as orexin-2 receptor agonists, specifically designed to improve activity, brain permeability, and safety profiles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing orexin-2 receptor agonist compounds are used, then some therapeutic effect is achieved, but activity, pharmacokinetics, brain permeability, and safety are unsatisfactory
Solution Approach 1:
The patent applies parameter changes by systematically modifying chemical structure parameters of orexin-2 receptor agonists. Specifically, the invention introduces a macrocyclic core structure with specific substituents (aromatic rings, heteroatoms, chain lengths) to optimize the balance between therapeutic efficacy and safety. The structural parameters including ring size, substituent positions, and molecular weight are carefully controlled to achieve improved brain permeability and pharmacokinetic properties while maintaining or enhancing therapeutic effect.
2Reliability
If existing orexin-2 receptor agonist compounds are used, then some therapeutic effect is achieved, but brain permeability is insufficient
Solution Approach 1:
The patent improves brain permeability by optimizing molecular parameters of the orexin-2 receptor agonists. The macrocyclic structure with controlled molecular weight, hydrophobicity, and three-dimensional conformation facilitates blood-brain barrier penetration. Specific structural features including the arrangement of aromatic substituents and the overall molecular compactness are designed to enhance CNS penetration while maintaining receptor affinity.
3Reliability
If compound structure is optimized for activity, then receptor agonist activity improves, but pharmacokinetic properties deteriorate
Solution Approach 1:
The patent achieves optimal pharmacokinetic activity balance through precise parameter control of the macrocyclic structure. The invention modifies parameters such as ring size (14-20 membered macrocycles), substituent types (aromatic, hetero aromatic, aliphatic), and their positions to simultaneously enhance receptor binding affinity and improve metabolic stability, half-life, and oral bioavailability. The macrocyclic framework provides structural rigidity that maintains binding pose while reducing metabolic degradation.
Data Source
AI summary
The present invention provides compounds useful for the treatment of narcolepsy or cataplexy in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.